Rare disease

Essential Thrombocythaemia

Clinical trials recruiting in Australia for Essential Thrombocythaemia, a rare disease, as the public registries list them.

Also called: ET; Essential thrombocytosis; Essential thrombocythemia; Primary thrombocythaemia; Primary thrombocythemia; Primary thrombocytosis

Follow this condition Browse A to Z Browse by body system

Sources: ClinicalTrials.gov, MedlinePlus, Orphanet Checked: 15 October 2026 Not medical advice

At a glance

9 trials recruiting in Australia

46 trials recruiting overseas

1-5 / 10 000 (Point prevalence, United States, Validated) prevalence

All ages age of onset

15 October 2026 date last checked

Trials in Australia

This Australian count is likely to be on the low side. It counts the trials this site files under this condition; the registry’s own search is broader and also returns closely related conditions, some of which have their own page here. If you are searching widely, check the registry as well — every trial below links to its own record.

  • Recruiting Phase 2

    Phase 2 study for people with Essential Thrombocythaemia

    Where
    • Linear Clinical Research, Nedlands (WA) — Recruiting
    • Western Health, Saint Albans (VIC) — Recruiting
    • St. Vincent's Hospital, Sydney (NSW) — Recruiting
    • Perth Blood Institute, West Perth (WA) — Recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Disc Medicine, Inc
    Timeline
    Started 6 June 2022 Today 16 October 2026 Estimated completion 1 May 2027

    NCT05320198 · Checked 11 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 3

    Phase 3 study for people with Essential Thrombocythaemia

    Where
    • Royal Prince Alfred Hospital ( Site 1003), Camperdown (NSW) — Recruiting
    • Royal North Shore Hospital ( Site 1001), St Leonards (NSW) — Recruiting
    • Sunshine Coast Hematology and Oncology Clinic ( Site 1006), Buderim (QLD) — Recruiting
    • Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002), Southport (QLD) — Recruiting
    • Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000), Adelaide (SA) — Recruiting
    • Monash Health ( Site 1004), Clayton (VIC) — Recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Merck Sharp & Dohme LLC
    Timeline
    Started 23 May 2024 Today 16 October 2026 Estimated completion 4 December 2034

    NCT06351631 · Checked 11 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 1

    Phase 1 study for people with Essential Thrombocythaemia

    Where
    • Macquarie University Hospital, Sydney (NSW) — Recruiting
    • Royal Adelaide Hospital, Adelaide (SA) — Recruiting
    • The Alfred Hospital, Melbourne (VIC) — Recruiting
    • Linear Clinical Research, Nedlands (WA) — Recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Incyte Corporation
    Timeline
    Started 1 October 2025 Today 16 October 2026 Estimated completion 14 March 2028

    NCT07008118 · Checked 11 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 3

    Phase 3 study for people with Essential Thrombocythaemia

    Where
    • Novartis Investigative Site, Adelaide (SA) — Recruiting
    • Novartis Investigative Site, Clayton (VIC) — Recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Novartis Pharmaceuticals
    Timeline
    Started 27 May 2026 Today 16 October 2026 Estimated completion 17 May 2028

    NCT07357727 · Checked 15 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 1

    Phase 1 study for people with Essential Thrombocythaemia

    Where
    • Concord General Repatriation Hospital, Concord (NSW) — Recruiting
    • Royal North Shore Hospital, St Leonards (NSW) — Recruiting
    • Icon Cancer Centre, Auchenflower (QLD) — Recruiting
    • Epworth Health Care, East Melbourne (VIC) — Recruiting
    • Linear Clinical Research, Nedlands (WA) — Recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Incyte Corporation
    Timeline
    Started 11 May 2026 Today 16 October 2026 Estimated completion 24 May 2030

    NCT07441694 · Checked 15 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 1

    Phase 1 study for people with Essential Thrombocythaemia

    Where
    • Scientia Clinical Research Ltd., Randwick (NSW) — Recruiting
    Who can join Age 18 Years to 55 Years. Sex Anyone, regardless of sex. Healthy volunteers Accepted.
    Sponsor Eilean Therapeutics AU Pty Ltd
    Timeline
    Started 16 April 2026 Today 16 October 2026 Estimated completion 1 November 2026

    NCT07527221 · Checked 11 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 2

    Phase 2 study for people with Essential Thrombocythaemia

    Where
    • St. Vincent's Hospital Sydney Limited, Sydney (NSW) — Recruiting
    • Macquarie University, Sydney (NSW) — Recruiting
    • Royal Adelaide Hospital, Adelaide (SA) — Recruiting
    • St Vincent's Hospital (Melbourne), Melbourne (VIC) — Recruiting
    • Monash Medical Centre, Melbourne (VIC) — Recruiting
    • The Perth Blood Institute Limited, Perth (WA) — Recruiting
    • Hollywood Private Hospital, Nedlands (WA) — Recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Jubilant Therapeutics Inc.
    Timeline
    Started 21 October 2024 Today 16 October 2026 Estimated completion 15 June 2028

    NCT07612280 · Checked 11 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 3

    Phase 3 study for people with Essential Thrombocythaemia

    Where

    No Australian site on this record is listed as recruiting right now, even though the trial itself is open. Check with the site or the official record before travelling.

    • Blacktown Cancer & Haematology Centre-Blacktown Hospital, Blacktown (NSW) — Not yet recruiting
    • Gosford Hospital (Gh) - Central Coast Cancer Centre, Gosford (NSW) — Not yet recruiting
    • Liverpool Hospital - South Western Sydney Local Health District, Liverpool (NSW) — Not yet recruiting
    • Sunshine Coast University Hospital, Birtinya (QLD) — Not yet recruiting
    • Royal Brisbane and Women'S Hospital, Brisbane (QLD) — Not yet recruiting
    • Peter Maccallum Cancer Centre, Melbourne (VIC) — Not yet recruiting
    • Box Hill Hospital, Melbourne (VIC) — Not yet recruiting
    • Rockingham General Hospital, Cooloongup — Not yet recruiting
    • The Canberra Hospital, Garran — Not yet recruiting
    • Royal Perth Hospital, Perth — Not yet recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Incyte Corporation
    Timeline
    Started 8 September 2026 Today 16 October 2026 Estimated completion 15 June 2029

    NCT07623200 · Checked 15 October 2026

    Trial details Summary for your GP Official record and contacts
  • Recruiting Phase 1

    Phase 1 study for people with Essential Thrombocythaemia

    Where
    • Site AU08, Liverpool (NSW) — Not yet recruiting
    • Site AU09, Sydney (NSW) — Recruiting
    • Site AU06, Melbourne (VIC) — Not yet recruiting
    • Site AU03, Melbourne (VIC) — Not yet recruiting
    Who can join Age 18 Years and over. Sex Anyone, regardless of sex. Healthy volunteers Not accepted.
    Sponsor Damora Therapeutics
    Timeline
    Started 1 September 2026 Today 16 October 2026 Estimated completion 1 June 2030

    NCT07849231 · Checked 14 October 2026

    Trial details Summary for your GP Official record and contacts

Trials overseas

46 trials for this disease are open to new participants outside Australia, as ClinicalTrials.gov listed them on 11 October 2026. Voxsanity does not publish a page for any of them; the searches below reach them at the registry.

These overseas counts are likely too high. They come from the registry’s own search, which expands a condition name to related conditions, so some of the trials counted are for a different disease in the same family.

Search ClinicalTrials.gov Search the WHO registry portal Joining a trial overseas

Trials not shown here

Some Australian trials are registered only on the Australian New Zealand Clinical Trials Registry and are not shown here. Search them at Australian Clinical Trials.

Key facts

Inheritance Multigenic/multifactorial; Not applicable
Genes TP53, JAK2, MPL, TET2, CALR, SH2B3
Prevalence 1-5 / 10 000 (Point prevalence, United States, Validated)
Age of onset All ages

Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com).

About Essential Thrombocythaemia

The text below is reproduced exactly as its source published it. It has not been edited, shortened or rewritten.

Essential thrombocythemia is a condition characterized by an increased number of platelets (thrombocythemia). Platelets (thrombocytes) are blood cells involved in blood clotting. While some people with this condition have no symptoms, others develop problems associated with the excess platelets. Abnormal blood clotting (thrombosis) is common in people with essential thrombocythemia and causes many signs and symptoms of this condition. Clots that block blood flow to the brain can cause strokes or temporary stroke-like episodes known as transient ischemic attacks. Thrombosis in the legs can cause leg pain, swelling, or both. In addition, clots can travel to the lungs (pulmonary embolism), blocking blood flow in the lungs and causing chest pain and difficulty breathing (dyspnea). Another problem in essential thrombocythemia is abnormal bleeding, which occurs more often in people with a very high number of platelets. Affected people may have nosebleeds, bleeding gums, or bleeding in the gastrointestinal tract. It is thought that bleeding occurs because a specific protein in the blood that helps with clotting is reduced, although why the protein is reduced is unclear. Other signs and symptoms of essential thrombocythemia include an enlarged spleen (splenomegaly); weakness; headaches; or a sensation in the skin of burning, tingling, or prickling. Some people with essential thrombocythemia have episodes of severe pain, redness, and swelling (erythromelalgia), which commonly occur in the hands and feet.

US source; availability in Australia may differ.

Source: MedlinePlus Genetics (medlineplus.gov), public domain (U.S. National Library of Medicine). Read the full source.

Sources and dates

  • ClinicalTrials.gov – trial records, statuses and site lists
  • MedlinePlus – the About text above, reproduced exactly
  • Orphanet / Orphadata – prevalence, age of onset, inheritance, genes and alternative names, used under CC BY 4.0
  • ClinicalTrials.gov processing date: 15 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Orphanet citation

Orphadata Science: Free access data from Orphanet. © INSERM 1999. Available on https://www.orphadata.com. Used under CC BY 4.0. Source: Orphanet / Orphadata (orphadata.com). Accessed 20 September 2026.

ORPHA:3318

Essential Thrombocythaemia is one of the rare diseases tracked on the Voxsanity rare disease hub, where you can compare it with every other rare condition we follow and filter trials by country.

Tell us which conditions matter to you

We use requests to help decide what to add next. Telling us about a condition is not a promise that we will add it, and we cannot say when any condition might appear.

We store the condition you name and the date you sent it. Nothing else: no email address, no name, and no link to any account. There is nothing here we could contact you with, so we will not email you as a result of this form. See our privacy policy.